The European Medicines Agency has accepted for review the Marketing Authorization Application for odronextamab to treat adult patients with relapsed/refractory follicular lymphoma or R/R diffuse large B-cell lymphoma, who have progressed after at least two prior systemic therapies. The EMA previously granted odronextamab Orphan Drug Designation for FL and DLBCL.
Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
